Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

66 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Eligibility Chronic Lymphocytic Leukemia NCT00201682

- 26/6/16 - 1 formulario, 2 itemgroups, 12 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00201682

Eligibility Leukemia NCT02280525

- 29/5/16 - 1 formulario, 2 itemgroups, 18 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cord Blood Natural Killer (NK) Cells in Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT02280525

Eligibility Chronic Lymphocytic Leukemia NCT02315768

- 9/5/16 - 1 formulario, 2 itemgroups, 26 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.; ODM derived from: https://clinicaltrials.gov/show/NCT02315768

Eligibility Chronic Lymphocytic Leukemia NCT02144623

- 9/5/16 - 1 formulario, 2 itemgroups, 18 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02144623

Eligibility Chronic Lymphocytic Leukaemia (CLL) NCT02273856

- 8/5/16 - 1 formulario, 2 itemgroups, 9 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL); ODM derived from: https://clinicaltrials.gov/show/NCT02273856

Eligibility Chronic Lymphocytic Leukemia NCT01465230

- 28/2/16 - 1 formulario, 2 itemgroups, 9 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01465230

Eligibility Chronic Lymphocytic Leukemia NCT01400685

- 28/2/16 - 1 formulario, 2 itemgroups, 14 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL; ODM derived from: https://clinicaltrials.gov/show/NCT01400685

Eligibility Chronic Lymphocytic Leukemia (CLL) NCT01463852

- 28/2/16 - 1 formulario, 2 itemgroups, 12 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT01463852

Eligibility Leukemia NCT00262782

- 24/2/16 - 1 formulario, 1 itemgroup, 17 items, 1 idioma
Itemgroup: Criteria
Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00262782

Eligibility 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), NCT01955668

- 27/11/15 - 1 formulario, 2 itemgroups, 31 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
AZD6738 First Time in Patient Multiple Ascending Dose Study; ODM derived from: https://clinicaltrials.gov/show/NCT01955668

CLL History BO17072 NCT00090051 - History of Chronic lymphocytic leukemia NCT0090051

- 3/11/15 - 1 formulario, 4 itemgroups, 9 items, 1 idioma
Itemgroups: History of CLL, Binet stage at screening, Previous chemotherapy, Previous chemotherapy
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072

CLL Follow-Up Disease tranformation BO17072 NCT00090051 - Follow-Up Disease tranformation of Chronic lymphocytic leukemia NCT0090051

- 28/10/15 - 1 formulario, 1 itemgroup, 4 items, 1 idioma
Itemgroup: Progressive disease due to transformation to an more aggressive histology
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial